Devices Paroled, Not Unconditionally, From Hill’s Drug Safety Hearings
This article was originally published in The Gray Sheet
Executive Summary
House Energy & Commerce and Senate HELP staffers differ slightly in their perceptions of medical device applicability to drug safety concerns, which are the preeminent FDA issue for the 109th Congress
You may also be interested in...
Heightened Device Postmarket Oversight Contingent On Drug Bill, FDA Report
Congress could consider specific device postmarket surveillance legislation if a report included in the drug safety bill concludes that intensified oversight is necessary, according to Hill staffers
Senate Bipartisan Clinical Trials Registry Bill Includes Device Firms
Medical device companies would be required to register clinical trials in a publicly accessible national databank as a condition of Institutional Review Board approval under a Senate bill introduced Feb. 28
Senate Bipartisan Clinical Trials Registry Bill Includes Device Firms
Medical device companies would be required to register clinical trials in a publicly accessible national databank as a condition of Institutional Review Board approval under a Senate bill introduced Feb. 28